Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
about
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@en
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@nl
type
label
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@en
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@nl
prefLabel
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@en
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@nl
P2860
P356
P1476
Cons: should immunotherapy be ...... f oncogene-driven lung cancer?
@en
P2093
Giulio Metro
Massimo Di Maio
P2860
P304
P356
10.21037/TLCR.2018.07.11
P407
P433
P577
2018-09-01T00:00:00Z